Sélectionner la langue
CD5
CD5 Informations sur la molécule
| Nom anglais | T-cell surface glycoprotein CD5 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 13 | Alias de la cible | Epididymis Secretory Sperm Binding Protein，CD5，Lymphocyte antigen T1/Leu-1，T-cell surface glycoprotein CD5，CD5 Molecule，CD5 Antigen (P56-62)，LEU1，CD5 Antigen，T1，CD5 Antigens |
| Phase de R&D la plus avancée | Phase 2 Clinical | ||
| Nom anglais | T-cell surface glycoprotein CD5 |
| Alias de la cible | Epididymis Secretory Sperm Binding Protein，CD5，Lymphocyte antigen T1/Leu-1，T-cell surface glycoprotein CD5，CD5 Molecule，CD5 Antigen (P56-62)，LEU1，CD5 Antigen，T1，CD5 Antigens |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 13 |
| Phase de R&D la plus avancée | Phase 2 Clinical |
CD5 Liste de produits
- Attribut
Protein (17)Antibody (2)Kits (1)Cell (1)
- Bibliothèque de produits
En ligne (21)
- Espèces
Human (14)Mouse (3)Rhesus macaque (3)Rabbit (1)
- Étiquette
His Tag (7)His Tag & Avi Tag (4)Fc Tag & Avi Tag (2)Fc Tag (4)- (4)
- Marqueur
Unconjugated (6)FITC Labeled (2)Biotin-labeled (6)PE Labeled (2)AF647 Labeled (1)AF488 Labeled (2)- (2)
Ajouter au panier
Quantité totale21
- 1
- 2
- 3
CD5Contexte de la molécule
T-cell surface glycoprotein CD5 is also known as Lymphocyte antigen T1/Leu-1 and LEU1,which is phosphorylated on tyrosine residues by LYN,so CD5 can create binding sites for PTPN6/SHP-1.CD5 may act as a receptor in regulating T-cell proliferation. CD5 is expressed at various developmental and activation stages on human B cells.CD5 is a well established negative regulator of TCR and BCR signalling.CD5-positive cells may also prevent the emergence of autoimmunity by provision of cytokines such as IL-10. Development,selection and function of different B- and T-cell subsets or their preferential survival may be directly or indirectly dependent on different glycan structures associated with CD5 or CD5-like molecules.
CD5Alias de la molécule
CD5,LEU1
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| CD5-targeted CAR-T cells therapy(Senlang Biotechnology) | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD5/CD7-Specific CAR-T Cells therapy(Essen Biotech) | BAH246; BAH-246; EB-BH2026 | Phase 2 Clinical | Essen Biotech | Central Nervous System Diseases; Leukemia, Prolymphocytic, T-Cell; Leukemia, T-Cell; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD5 CAR T Cells therapy(Beijing GoBroad Hospital) | Phase 2 Clinical | Beijing GoBroad Hospital | Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| MB-105(March Biosciences) | MB-105(March Biosciences) | Phase 2 Clinical | March Biosciences Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| anti-CD5 CAR T-cell therapy (Beijing Boren Hospital) | Phase 1 Clinical | Beijing Gao Boren Hospital Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD5CAR | CD5CAR | Phase 1 Clinical | iCell Gene Therapeutics LLC | Lymphoma, Non-Hodgkin; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CT-125A | CT-125A; RD-125 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Plasmablastic Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD5 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) thrapy(Precision Biotechnology) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD5 CAR T-cells therapy(Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| AB-205 (Artiva Biotherapeutics/GC Cell) | CD5 CAR-NK; GCC-2005; GL-205; GCC2005 | Phase 1 Clinical | GC Cell Corp | Lymphoma, T-Cell | Details |
| Autologous CAR-T cell therapy(Vittoria Biotherapeutics) | VIPER-101; Senza5 CART5; VIPER101 | Phase 1 Clinical | Vittoria Biotherapeutics Inc | Lymphoma, T-Cell | Details |
| CD5 CAR T-Cells (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, Non-Hodgkin; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD5 CAR-T Therapy(Xuanwu Hospital) | Phase 1 Clinical | Xuanwu Hospital Of Capital Medical University | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :